TScan Therapeutics’ (TCRX) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note released on Tuesday morning, Benzinga reports. Wedbush currently has a $10.00 price objective on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Thursday, March 7th.

TScan Therapeutics Price Performance

Shares of TCRX opened at $7.32 on Tuesday. The firm has a 50-day simple moving average of $7.19 and a two-hundred day simple moving average of $5.82. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.51 and a quick ratio of 6.51. TScan Therapeutics has a 1-year low of $1.62 and a 1-year high of $9.00. The stock has a market cap of $350.48 million, a PE ratio of -3.87 and a beta of 0.90.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. The business had revenue of $7.21 million during the quarter, compared to analyst estimates of $2.94 million. As a group, analysts forecast that TScan Therapeutics will post -1.03 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TCRX. Letko Brosseau & Associates Inc. purchased a new position in TScan Therapeutics in the third quarter worth approximately $83,000. Pale Fire Capital SE purchased a new position in TScan Therapeutics in the third quarter worth approximately $42,000. abrdn plc purchased a new position in TScan Therapeutics in the fourth quarter worth approximately $1,166,000. Finally, Cannon Global Investment Management LLC purchased a new position in TScan Therapeutics in the first quarter worth approximately $139,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.